Compare Globus Medical Inc. Class A Common Stock (GMED) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $92.27 (market cap $5.70B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and State Street SPDR Bloomberg High Yield Bond ETF for 63 Days on average.
| GMED | JNK | |
|---|---|---|
Market Cap | $10.25B | $5.70B |
Volume | 1,108,124 | 1,722,684 |
Sector | Health | Fixed Income |
52-Week High | $96.82 | $98.02 |
52-Week Low | $58.33 | $92.25 |
Typical Hold Time | 0 Days | 63 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
JNK trades at $92.66, down 0.29% amid a bearish technical outlook with selling pressure across moving averages and oscillators. The ETF shows consistent dividend payments of $0.53 but lacks fundamental ratio data. Recent market focus centers on rising bond yields and geopolitical tensions affecting high-yield bond markets.
Outlook remains cautious as technical indicators signal bearish momentum with RSI at overbought levels. Investment opportunities include steady dividend income, while risks involve sensitivity to interest rate hikes and broader bond market volatility. The ETF's performance is closely tied to credit market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
